L-/N-type Calcium Channel Blockers and Proteinuria

ISSN: 1875-6506 (Online)
ISSN: 1573-4021 (Print)

Volume 13, 2 Issues, 2017

Download PDF Flyer

Current Hypertension Reviews

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Prof. Kazuomi Kario
Jichi Medical University
School of Medicine

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

L-/N-type Calcium Channel Blockers and Proteinuria

Current Hypertension Reviews, 9(3): 210-218.

Author(s): Katsuyuki Ando.

Affiliation: Department of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, 7-3- 1 Hongo, Bunkkyo-ku, Tokyo, 113-8655, Japan.


The first-line depressor agents for hypertensive patients with chronic kidney disease are the renin-angiotensin system inhibitors because of their antiproteinuric and reno-protective effects. However, only one renin-angiotensin system inhibitor often cannot achieve target blood pressure in patients with injured kidney. Thus, second-line antihypertensives are required. Calcium channel blockers are frequently added on the renin-angiotensin system inhibitors in hypertensive patients with chronic kidney disease. However, they do not always show reno-protective effects because of their glomerular pressure-increasing action; Antihypetensive calcium channel blockers suppress L-type calcium channels, which exist in glomerular afferent but not efferent arterioles, and their afferent arteriole-specific vasodilation causes glomerular hypertension. The decrease in glomerular pressure due to their systemic hypotesive effect is counteracted by the glomerular pressure-incresing action. However, L-/N-type calcium channel blockers inhibits norepinephrine release from the sympathetic nerve terminal by blockade of N-type calcium channels, and dilate both afferent and efferent arterioles, which were innervated sympathetically, resulting in decrease in glomerular pressure. Actually, we have demonstrated that an L-/N-type calcium channel blocker cilnidipine decreased urinary protein more greatly than an L-type calcium channel blocker amlodipine in the renin-angiotensin system inhibitor-treated patients with chronic kidney disease. Thus, L-/N-type calcium channel blockers are one of suitable candidates for the second-line antihypertensives in the renin-angiotensin system inhibitor-treated hypertensive patients with proteinuria.


N-type calcium channel, chronic kidney disease, afferent arteriole, glomerular pressure, sympathetic nervous system.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 3
First Page: 210
Last Page: 218
Page Count: 9
DOI: 10.2174/1573402110666140131155331
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science